Endo Pharma ends collaboration on back pain drug – BusinessWeek
Endo Pharma ends collaboration on back pain drug BusinessWeek Endo Pharmaceuticals Holdings Inc. said Wednesday that it is ending a partnership on an experimental back pain drug.
Read more here:
Endo Pharma ends collaboration on back pain drug – BusinessWeek
Endo Pharma ends collaboration on back pain drug – Forbes
Endo Pharma ends collaboration on back pain drug Forbes Endo Pharmaceuticals Holdings Inc. said Wednesday that it is ending a partnership on an experimental back pain drug. Endo announced June 30 that the drug, axomadol, did not meet its main goal in a clinical trial that tested its ability to treat …
View post:
Endo Pharma ends collaboration on back pain drug – Forbes
Endo Pharma’s lower back pain drug fails trial – Reuters
Endo Pharma's lower back pain drug fails trial Reuters June 30 (Reuters) – Endo Pharmaceuticals Holdings Inc said its experimental drug to treat lower back pain did not meet the goals of a mid-stage trial and it was evaluating the future of the drug. The drug, axomadol, was being tested against a placebo … Endo Pharmaceuticals back pain drug disappoints in trials Bizjournals.com Endo Pharma's Low- Back Pain Treatment Misses Study Goals NASDAQ Endo Pharmaceuticals Investor’s Business Daily MarketWatch (press release) all 20 news articles??
Read the original here:
Endo Pharma’s lower back pain drug fails trial – Reuters
Consider ER oxymorphone in patients with chronic low back pain, comorbidities – ModernMedicine
Consider ER oxymorphone in patients with chronic low back pain , comorbidities ModernMedicine In patients with chronic low back pain (CLBP) with comorbidities such as hypertension, diabetes, and cardiovascular disease (CVD), extended-release oxymorphone (Opana ER, Endo Pharmaceuticals) may be a safe and effective alternative, according to a …
Read the rest here:
Consider ER oxymorphone in patients with chronic low back pain, comorbidities – ModernMedicine
FDA panel rejects Jazz drug for pain condition – AP – msnbc.com
Federal health experts said Friday the risks of a sleep drug from Jazz Pharmaceuticals outweigh its benefits for treating the chronic pain disorder fibroymalgia. The Food and Drug Administration’s panel of outside …
Read the original here:
FDA panel rejects Jazz drug for pain condition – AP – msnbc.com
DURECT Corporation Announces First Quarter 2010 Financial Results – MarketWatch (press release)
Posted in: Back Pain News Tags: announces-first, back-pain, chronic-low, financial, financial-results, pharmaceuticals, phase, press-release, safety, the-safety, trial-evaluating
DURECT Corporation Announces First Quarter 2010 Financial Results MarketWatch (press release) In April 2010, King Pharmaceuticals initiated a Phase IIb trial evaluating the safety and efficacy of ELADUR in patients with chronic low back pain .
Read more from the original source:
DURECT Corporation Announces First Quarter 2010 Financial Results – MarketWatch (press release)
King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain
Posted in: Back Pain News Tags: chronic-low, clinical-trial, corporation, deliver-bupivacaine, drug-patch, pharmaceuticals, phase, treatment
DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain . ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.
See more here:
King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain